Clinical Trials Browser

OTHER × Pathologic Complete Response × pyrotinib × Clear all

NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms